TRVN vs. CANF, CLVR, EFTR, GRAY, PTIX, TENX, YMTX, ADIL, KA, and KTTA
Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Can-Fite BioPharma (CANF), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), Graybug Vision (GRAY), Protagenic Therapeutics (PTIX), Tenax Therapeutics (TENX), Yumanity Therapeutics (YMTX), Adial Pharmaceuticals (ADIL), Kineta (KA), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical preparations" industry.
Trevena (NASDAQ:TRVN) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk.
13.6% of Trevena shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 2.4% of Trevena shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Trevena has a net margin of 0.00% compared to Can-Fite BioPharma's net margin of -1,027.46%. Can-Fite BioPharma's return on equity of -113.75% beat Trevena's return on equity.
In the previous week, Trevena had 2 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 3 mentions for Trevena and 1 mentions for Can-Fite BioPharma. Trevena's average media sentiment score of 0.25 beat Can-Fite BioPharma's score of 0.00 indicating that Trevena is being referred to more favorably in the media.
Can-Fite BioPharma has lower revenue, but higher earnings than Trevena. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
Trevena has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.
Trevena received 614 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 72.10% of users gave Trevena an outperform vote while only 2.44% of users gave Can-Fite BioPharma an outperform vote.
Trevena currently has a consensus price target of $9.00, suggesting a potential upside of 2,097.80%. Can-Fite BioPharma has a consensus price target of $15.00, suggesting a potential upside of 638.92%. Given Trevena's higher possible upside, analysts plainly believe Trevena is more favorable than Can-Fite BioPharma.
Summary
Trevena beats Can-Fite BioPharma on 9 of the 16 factors compared between the two stocks.
Get Trevena News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
